What the trial was testing
The ANCHOR enrolled 276 patients with asthma. The study was sponsored by GlaxoSmithKline and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Depemokimab shrank nasal polyps and reduced nasal blockage more than placebo in two studies of 528 people.
Lancet (London, England) · 2025 · NCT05274750
These findings — that people on depemokimab had measurably smaller nasal polyps after one year compared to placebo. — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 276 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with asthma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Depemokimab is not yet FDA-approved for nasal polyps. The trial results were positive and published in a major journal, which often leads to approval within 1–2 years. If you have severe nasal polyps that haven't responded to surgery or steroids, talk to your doctor about whether you qualify for ongoing trials or similar approved treatments.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open asthma trials
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5. Recently, RCTs proved the efficacy and safety of fixed triple combinations of moderate and high dose of ICS and LABA, LAMA in a very selected asthmatic population, resulting in the market authorisation of these products. However, there is a lack of evidence on the real-world effectiveness of these therapies, especially with regards to improvement in symptom scores and quality of life. Also, there is scarcity of data regarding the phenotypes of asthmatics who benefit the most from the use of fixed triple combinations.
Expressions of Ezrin and Pip5k1α Proteins in Airway Smooth Muscle of Asthmatic Patients
Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients. Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear. Pip5k1α is an important kinase involved in intracellular phosphatidylinositol signalling pathways that may be involved in smooth muscle contraction and diastole. Therefore, further studies are necessary to elucidate the changes of Ezrin and Pip5k1α in patients with asthma to provide a basis for investigating alternative treatments for asthma.